PATIENT PROFILES

Bill, age 59.  Wants to fight his cancer, but also wants to know what side effects are related to his treatment.
TREATMENT PROFILE
Fred, age 64.  Is prepared to fight, but curious about the tolerability of different treatment options.
TREATMENT PROFILE
James, age 78.  Wants to continue with treatment and learn about what side effects he can expect.
TREATMENT PROFILE
Bill, age 59. Wants to fight his cancer, but also wants to know what side effects are related to his treatment.
Open link
Alt text

"I want to fight my cancer, but I also want to know what side effects are related to my treatment."

 

  • Attorney who travels for business
  • Focuses on his professional appearance
  • Stays active and enjoys the outdoors

 

Treatment goals:

Bill wants a proven treatment with a well-established safety profile.

    TREATMENT HISTORY
    patient Bill, mCRPC treatment history and clinical characteristics
    Alt tag

    For Bill, what is your choice for an effective treatment with a well-established safety profile?

    Image alt
    Learn more
    Open link
     
    Fred, age 64. Is prepared to fight, but curious about the tolerability of different treatment options.
    Open link
    Alt text

    "I am prepared to fight, but what about the tolerability of my treatment options?"

     

    • Runs his own accounting firm and is an avid golfer
    • Married father of 2 grown children
    • Maintains a busy work and social schedule

     

    Treatment goals:

    Fred wants a treatment with both proven efficacy and a well-established safety profile.

      TREATMENT HISTORY
      Fred patient history breakdown, looking into clinical characteristics and mCRPC treatment history
      Alt tag

      For Fred, what is your choice for an effective treatment with a well-established safety profile?

      Image alt
      Learn more
      Open link

      Important Safety Information (cont'd)

      Warnings and Precautions (cont'd)

      Bone Marrow Suppression (cont'd): For 7 of 13 patients treated with Xofigo bone marrow failure was ongoing at the time of death. Among the 13 patients who experienced bone marrow failure, 54% required blood transfusions. Four percent (4%) of patients in the Xofigo arm and 2% in the placebo arm permanently discontinued therapy due to bone marrow suppression.

      Please see additional Important Safety Information below.

       
      James, age 78. Wants to continue with treatment and learn about what side effects he can expect.
      Open link
      Alt text

      "I want to continue with treatment, but what side effects can I expect from my options?"

       

      • Retired businessman who enjoys playing chess and board games
      • Widowed 5 years ago, but has the strong support of his 3 sons and grandchildren
      • Enjoys monthly visits with his grandchildren

       

      Treatment goals:

      Effective cancer treatment with a well-established safety profile is important to James.

        TREATMENT HISTORY
        James treatment history with mHSPC
        Alt tag

        For James, what is your choice for an effective treatment with a well-established safety profile?

        Image alt
        Learn more
        Open link

        TIMING OF XOFIGO TREATMENT IS CRITICAL

        Start Xofigo or refer to a treatment site when your patient has the following

        Alt tag

        Rising PSA on androgen deprivation therapy with testosterone ≤50 ng/dL, indicating castration-resistant prostate cancer1a

        Alt tag

        Symptoms attributable to bone metastases2

        Alt tag

        ≥2 bone metastases2

        Alt tag

        No known visceral metastases2

        Also consider for patients who

        • Have lymphadenopathy up to 3 cm in the short axis2
        • Are referred for external-beam radiation therapy (EBRT) as part of best standard of care (BSOC)b

         

        aSerum PSA progression defined as 2 consecutive increases in PSA over a previous reference.

        bIn the ALSYMPCA clinical trial, Xofigo was given with BSOC, which included antiandrogens, ketoconazole, local EBRT, estrogens, estramustine, or treatment with glucocorticoids.3

         

        References
        • Scher HI, Morris MJ, Stadler WM, et al. Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the prostate cancer clinical trials working group 3. J Clin Oncol. 2016;34(12):1402-1418. Return to content
        • Xofigo® (radium Ra 223 dichloride) injection [prescribing information].Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc.; December 2019. Return to content
        • Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369(3):213-223. Return to content
        Image alt
        Plan MCRPC treatment
        MCRPC treatment"},{"trigger":"click","key":"eventValue"},{"trigger":"click","key":"event","value":"gaGenericEvent"}]" >Open link

        Indication

        Xofigo is indicated for the treatment of patients with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastatic disease.

        Important Safety Information

        Warnings and Precautions:
        • Bone Marrow Suppression: In the phase 3 ALSYMPCA trial, 2% of patients in the Xofigo arm experienced bone marrow failure or ongoing pancytopenia, compared to no patients treated with placebo. There were two deaths due to bone marrow failure. For 7 of 13 patients treated with Xofigo bone marrow failure was ongoing at the time of death. Among the 13 patients who experienced bone marrow failure, 54% required blood transfusions. Four percent (4%) of patients in the Xofigo arm and 2% in the placebo arm permanently discontinued therapy due to bone marrow suppression. In the randomized trial, deaths related to vascular hemorrhage in association with myelosuppression were observed in 1% of Xofigo-treated patients compared to 0.3% of patients treated with placebo. The incidence of infection-related deaths (2%), serious infections (10%), and febrile neutropenia (<1%) was similar for patients treated with Xofigo and placebo. Myelosuppression–notably thrombocytopenia, neutropenia, pancytopenia, and leukopenia–has been reported in patients treated with Xofigo.

          Monitor patients with evidence of compromised bone marrow reserve closely and provide supportive care measures when clinically indicated. Discontinue Xofigo in patients who experience life-threatening complications despite supportive care for bone marrow failure

         

        • Hematological Evaluation: Monitor blood counts at baseline and prior to every dose of Xofigo. Prior to first administering Xofigo, the absolute neutrophil count (ANC) should be ≥1.5 × 109/L, the platelet count ≥100 × 109/L, and hemoglobin ≥10 g/dL. Prior to subsequent administrations, the ANC should be ≥1 × 109/L and the platelet count ≥50 × 109/L. Discontinue Xofigo if hematologic values do not recover within 6 to 8 weeks after the last administration despite receiving supportive care

         

        • Concomitant Use With Chemotherapy: Safety and efficacy of concomitant chemotherapy with Xofigo have not been established. Outside of a clinical trial, concomitant use of Xofigo in patients on chemotherapy is not recommended due to the potential for additive myelosuppression. If chemotherapy, other systemic radioisotopes, or hemibody external radiotherapy are administered during the treatment period, Xofigo should be discontinued

         

        • Increased Fractures and Mortality in Combination With Abiraterone Plus Prednisone/Prednisolone: Xofigo is not recommended for use in combination with abiraterone acetate plus prednisone/prednisolone outside of clinical trials. At the primary analysis of the phase 3 ERA-223 study that evaluated concurrent initiation of Xofigo in combination with abiraterone acetate plus prednisone/prednisolone in 806 asymptomatic or mildly symptomatic mCRPC patients, an increased incidence of fractures (28.6% vs 11.4%) and deaths (38.5% vs 35.5%) have been observed in patients who received Xofigo in combination with abiraterone acetate plus prednisone/prednisolone compared to patients who received placebo in combination with abiraterone acetate plus prednisone/prednisolone. Safety and efficacy with the combination of Xofigo and agents other than gonadotropin-releasing hormone analogues have not been established

         

        • Embryo-Fetal Toxicity: The safety and efficacy of Xofigo have not been established in females. Xofigo can cause fetal harm when administered to a pregnant female. Advise pregnant females and females of reproductive potential of the potential risk to a fetus. Advise male patients to use condoms and their female partners of reproductive potential to use effective contraception during and for 6 months after completing treatment with Xofigo

         

        Administration and Radiation Protection: Xofigo should be received, used, and administered only by authorized persons in designated clinical settings. The administration of Xofigo is associated with potential risks to other persons from radiation or contamination from spills of bodily fluids such as urine, feces, or vomit. Therefore, radiation protection precautions must be taken in accordance with national and local regulations

        Fluid Status: Dehydration occurred in 3% of patients on Xofigo and 1% of patients on placebo. Xofigo increases adverse reactions such as diarrhea, nausea, and vomiting, which may result in dehydration. Monitor patients’ oral intake and fluid status carefully and promptly treat patients who display signs or symptoms of dehydration or hypovolemia

        Injection Site Reactions: Erythema, pain, and edema at the injection site were reported in 1% of patients on Xofigo

        Secondary Malignant Neoplasms: Xofigo contributes to a patient’s overall long-term cumulative radiation exposure. Long-term cumulative radiation exposure may be associated with an increased risk of cancer and hereditary defects. Due to its mechanism of action and neoplastic changes, including osteosarcomas, in rats following administration of radium-223 dichloride, Xofigo may increase the risk of osteosarcoma or other secondary malignant neoplasms. However, the overall incidence of new malignancies in the randomized trial was lower on the Xofigo arm compared to placebo (<1% vs 2%; respectively), but the expected latency period for the development of secondary malignancies exceeds the duration of follow-up for patients on the trial

        Subsequent Treatment With Cytotoxic Chemotherapy: In the randomized clinical trial, 16% of patients in the Xofigo group and 18% of patients in the placebo group received cytotoxic chemotherapy after completion of study treatments. Adequate safety monitoring and laboratory testing was not performed to assess how patients treated with Xofigo will tolerate subsequent cytotoxic chemotherapy

        Adverse Reactions: The most common adverse reactions (≥10%) in the Xofigo arm vs the placebo arm, respectively, were nausea (36% vs 35%), diarrhea (25% vs 15%), vomiting (19% vs 14%), and peripheral edema (13% vs 10%). Grade 3 and 4 adverse events were reported in 57% of Xofigo-treated patients and 63% of placebo-treated patients. The most common hematologic laboratory abnormalities in the Xofigo arm (≥10%) vs the placebo arm, respectively, were anemia (93% vs 88%), lymphocytopenia (72% vs 53%), leukopenia (35% vs 10%), thrombocytopenia (31% vs 22%), and neutropenia (18% vs 5%)

        For important risk and use information about Xofigo, please see the Full Prescribing Information.

        You are encouraged to report side effects or quality complaints of products to the FDA by visiting www.fda.gov/medwatch or calling 1-800-FDA-1088. For Bayer products, you can report these directly to Bayer by clicking here.

        © 2022 Bayer. All rights reserved. June 2022

        Bayer, the Bayer Cross, Xofigo, and the Xofigo Access Services logo are registered trademarks of Bayer.

        Site Last Modified: 06/22

        THIS SITE IS FOR US AUDIENCES ONLY.